Zacks Investment Research upgraded shares of Menlo Therapeutics (NASDAQ:MNLO) from a hold rating to a buy rating in a report released on Wednesday morning. Zacks Investment Research currently has $6.25 target price on the stock.

According to Zacks, “Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company’s product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California. “

Several other analysts have also recently issued reports on MNLO. Jefferies Financial Group cut their target price on Menlo Therapeutics to $7.00 and set a hold rating for the company in a research report on Tuesday, October 9th. Cantor Fitzgerald reiterated a buy rating and set a $25.00 target price on shares of Menlo Therapeutics in a research report on Wednesday, November 7th. Finally, ValuEngine upgraded Menlo Therapeutics from a hold rating to a buy rating in a research report on Thursday, November 1st. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $24.32.

NASDAQ MNLO opened at $5.56 on Wednesday. Menlo Therapeutics has a 52 week low of $3.74 and a 52 week high of $39.86. The stock has a market capitalization of $127.31 million and a PE ratio of -0.98.

Menlo Therapeutics (NASDAQ:MNLO) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.33. Menlo Therapeutics had a negative return on equity of 41.70% and a negative net margin of 268.61%. On average, research analysts expect that Menlo Therapeutics will post -2.48 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in MNLO. Virtu Financial LLC purchased a new position in Menlo Therapeutics during the 3rd quarter valued at approximately $126,000. Trexquant Investment LP purchased a new position in Menlo Therapeutics during the 3rd quarter valued at approximately $151,000. TIAA CREF Investment Management LLC purchased a new position in Menlo Therapeutics during the 3rd quarter valued at approximately $184,000. Tekla Capital Management LLC purchased a new position in Menlo Therapeutics during the 3rd quarter valued at approximately $244,000. Finally, Renaissance Technologies LLC purchased a new position in Menlo Therapeutics during the 3rd quarter valued at approximately $308,000. Hedge funds and other institutional investors own 70.20% of the company’s stock.

Menlo Therapeutics Company Profile

Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis.

Recommended Story: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Menlo Therapeutics (NASDAQ:MNLO)

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.